Pod těmito názvy můžete látku najít v jiných zdrojích
CELL-BASED GENE THERAPY CONSISTING OF A GENETICALLY MODIFIED CELL LINE, DERIVED FROM HUMAN DONOR-DERIVED RETINAL PIGMENT EPITHELIAL (RPE) CELLS. THE CELL LINE WAS TRANSFECTED SEQUENTIALLY WITH TWO PLASMIDS (P834 AND P910) EXPRESSING THE SAME FUSION PROTEIN COMPOSED OF: SIGNAL PEPTIDE AND DOMAIN 2 OF VEGFR1 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1, FLT1) (VEGFR1(D2)); DOMAIN 3 OF VEGFR2 (VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2, KDR) (VEGFR2(D3)); AND HINGE DOMAIN, CH2 REGION AND CH3 REGION OF HUMAN IMMUNOGLOBULIN G1 (IGG1) UNDER THE CONTROL OF A PROMOTER CONTAINING A MOUSE CYTOMEGALOVIRUS (MCMV) ENHANCER, THE HUMAN ELONGATION FACTOR 1-ALPHA (EF1-ALPHA) CORE PROMOTER AND A SYNTHETIC INTRON (I 126).